![BIEBL; KONSTANTIN: NOVÝ IKAROS. - 1929. 2. vyd. Ot. Štorch - Narien; Aventinum sv; 223; úprava FRANTIŠEK MUZIKA. – Antikvariát Pražský Almanach BIEBL; KONSTANTIN: NOVÝ IKAROS. - 1929. 2. vyd. Ot. Štorch - Narien; Aventinum sv; 223; úprava FRANTIŠEK MUZIKA. – Antikvariát Pražský Almanach](https://cdn.shopify.com/s/files/1/1040/0892/products/105829_b69b3c9b-5d8d-4ce7-8228-e1312e118571.jpg?v=1486830025)
BIEBL; KONSTANTIN: NOVÝ IKAROS. - 1929. 2. vyd. Ot. Štorch - Narien; Aventinum sv; 223; úprava FRANTIŠEK MUZIKA. – Antikvariát Pražský Almanach
![PDF) Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4 PDF) Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4](https://www.researchgate.net/publication/282568515/figure/fig7/AS:293081447452688@1446887470547/RNA-mediated-knockdown-of-IKZF1-or-IKZF3-leads-to-the-downregulation-of-c-Myc-and-IRF4_Q320.jpg)
PDF) Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
![PDF) Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4 PDF) Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4](https://www.researchgate.net/publication/282568515/figure/fig4/AS:293081439064068@1446887469220/RNA-mediated-knockdown-of-IKZF1-or-IKZF3-inhibits-proliferation-and-induces-apoptosis-in_Q320.jpg)
PDF) Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
![PDF) Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4 PDF) Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4](https://i1.rgstatic.net/publication/282568515_Rate_of_CRL4CRBN_substrate_Ikaros_and_Aiolos_degradation_underlies_differential_activity_of_lenalidomide_and_pomalidomide_in_multiple_myeloma_cells_by_regulation_of_c-Myc_and_IRF4/links/563dc02c08ae8d65c0125d05/largepreview.png)